Peregrine Pharmaceuticals (PPHM): AAI Conf. starts tommorrow; Thorpe Mon+Wed...

Upgrade Today! Level II Pinks & OTCBB from only $29.99

Listed & Nasdaq | Biotechs | Peregrine Pharmaceuticals (PPHM)

Public Reply | Private Reply | Keep | Last Read

Posted by: cjgaddy	Date: Friday, April 01, 2005 5:20:36 PM
In reply to: None	Post # of 55981

AAI Conf. starts tommorrow; Thorpe Mon+Wed...

Apr 2-6, 2005: “American Assoc. of Immunologists (AAI) 2005 Annual Meeting”, San Diego
http://www.aai.org/EB2005/default.htm
“Where the cures of tomorrow can be seen in the science of today… More than 16,000 biological and biomedical scientists will gather for Experimental Biology 2005. It is designed to bring together scientists from dozens of different disciplines, from laboratory to translational to clinical research, from throughout the U.S. and across the world. In literally thousands of presentations, symposia, workshops, and poster sessions, they share information across the boundaries of their own fields and present the newest scientific concepts and discoveries shaping medical advances for today and the future…”

Note: Peregrine’s 2-8-05 PR (‘Drs. Marx & Smith join PPHM’s SRB’) said, “Data relating to the evaluation of Peregrine's Anti-Phospholipid Therapy (APT) technology to treat viral diseases will be presented at the AAI conference Apr2-6 2005”.

AAI Presentation: ”Targeting inside-out phospholipids on viruses in a guinea pig model of Lassa fever”
Authors: M.M. Soares and P.E. Thorpe
Session Type: Vaccines and Immunotherapy for Infectious Disease
April4/mon 12:30-1:30pm #551/Poster Presentation:
http://www.eb2005-online.com/viewabstract.php?id=6277
April6/wed 9:45am #1002/Podium Oral Presentation:
http://www.eb2005-online.com/viewabstract.php?id=2252

ABSTRACT:
Enveloped viruses acquire their envelope from the plasma membrane of the host cell upon egress. The plasma membrane of the cell is asymmetric with the anionic phospholipids, such as phosphatidylserine (PS), positioned on the inner (cytosolic) surface. We hypothesized that PS would become exposed on the external surface of the viral envelope because of lipid movements during the fission process. If so, anti-PS antibodies might interfere with viral entry, egress, mediate virus clearance in vivo or direct host mechanisms to kill infected cells. To test this hypothesis, we developed a chimeric antibody Tarvacin, against PS and used it to treat Pichinde virus infection in guinea pigs. We confirmed that Tarvacin binds to external PS on both Pichinde virions and Pichinde virus-infected cells. When lethally infected outbred guinea pigs were treated with Tarvacin 18hrs after infection, 50% of them survived. More importantly, treatment of guinea pigs that had overt disease symptoms also resulted in the recovery of 50% of the animals. Animals that survived gained weight steadily and did not display physical symptoms of the disease. There were no observable toxicities associated with the therapy. These results indicate that anionic phospholipids such as PS might serve as important targets for the treatment of viral disease.
Work supported by NIH grant 1U01A1056412-01
M. Melina Soares, Philip E. Thorpe. Dept. of Pharmacology, Univ. of Texas SW Medical Center, 2201 Inwood Rd., Dallas, TX

= = = = = = = = = = = = = = = = = = = =
FYI, link to NIAID 8-2003 $1.68mm grant to Thorpe for Anti-PS/3G4 treatment of Lassa Fever ("The information generated by these studies may also extend to other viruses that could be used for bioterrorism purposes"):
http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=6855134&p_grant_num=5U01AI056412-03&....

Also, link to Thorpe’s patent app #20040161429 (filed 8-15-03, pub. USPO 8-19-04), titled “Compositions for treating Viral Infections using Immunoconjugates to Aminophospholipids”:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fn....

[0909] “the spectrum of viral treatment for the present invention extends to any virus, whether enveloped or not, DNA or RNA. …the invention is not limited to the treatment of enveloped viruses alone, nor to any particular virus, which is an important advantage.”

[0913] “In terms of naturally occurring viruses and the resultant diseases, the invention is again unlimited in its applications. Accordingly, any one or more of the viruses in Table J [100+ viruses listed, incl. AIDS] may be inhibited using the present invention, and the resultant infections and diseases thus treated.”

[1298] “The 3G4 antibody has also been administered to monkeys in safety studies and no side effects have been observed.”

[1302] “the 3G4 antibody has enormous potential as a broad spectrum anti-viral agent.”

[1303] “The 3G4 antibody thus possesses the combined properties of an anti-angiogenic, anti-tumor vascular and anti-viral agent. The inhibitory activities of 3G4 on cell division, angiogenesis, tumor growth and viral infectivity, taken together with lack of apparent toxicity, show broad therapeutic indications for this antibody, including in the treatment of angiogenic disorders, cancer, diabetes and viral infections.”

[0015] “The development of agents capable of treating both cancer and viral infections, two of the most significant medical challenges of this era, would be a remarkable and important breakthrough.”

[0028] “the invention further provides an important new class of compositions and methods for inhibiting viral replication, infection and spread for use in treating viral infections and diseases.”

[0030] “The development of new safe, therapeutic agents effective in the treatment of aberrant angiogenesis, cancer and viral infections and diseases is thus a breakthrough in the art.”

Finally, Thorpe's 10-25-04 “Understanding Tarvacin” presentation, incl. his first-ever public comments about Tarvacin's ANTI-VIRAL capabilities (at Peregrine SHM):
”OK, this is Tarvacin.. the cleanest tumor vessel marker of which we are aware.. If you look here at the 3G4 slide, you'll see, most remarkably, that it's absolutely chock full with macrophages. Every one of those is a macrophage and there's so many of them that they're beginning to outnumber the tumor cells. So you can see the reaction that's being mounted against the tumor.. And if you take the drugs together (3G4 + Docetaxel), practically none of the Lungs have any sign of disease. It's quite impressive… Pancreatic cancer is a killer.. you see that combination (3G4 + Gemcitabine) has dropped the number of metastases in the liver by, oh, that looks like more than 90% to me.. and that's exactly what we hope to do with humans.. 3G4 combines beautifully with radiation to treat Lung cancer.. here, rodents were infected with Lassa Fever virus, a very lethal virus.. if the animals were getting Tarvacin, half the animals rejected the virus and went on to live normally. That's an extraordinary result, I don't know of any other antiviral agent that is known to protect against Lassa Fever. And we've also shown similar results in cytomegalovirus... at that dose we've never seen any sign of toxicity in mice or monkeys; about 14 species treated with the therapeutic dose. And that's thousands of mice monkeys. And even if you increase the dose to 10 mg/kg, that's 10x the therapeutic dose.. So the conclusions with Tarvacin are that it has a unique mechanism of action, there's nothing else like it out there; it homes specifically to tumor blood vessels and induces white blood cells to attack the tumor.”
View: http://www.peregrineinc.com/content.php?id=174
Read: http://www.investorshub.com/boards/read_msg.asp?message_id=4440307

Peregrine Pharmaceuticals (PPHM) Stock Trading Info:

Public Reply | Private Reply | Keep | Last Read

Next 10 | Previous | Next

Add Peregrine Pharmaceuticals (PPHM) To Favorites

Keyboard Shortcuts

Report TOS Violation


Current Price
Change
Volume
Detailed Quote - Discussion Board

+/- to Watchlist

About Us | User Agreement |

Site Map & FAQs | Contact Us | Advertising | New Stuff Blog | Stock Market 101